Istituto DI Ricerche Farmacologiche Mario Negri
Milano, Lombardia
- UEI
- TN35LLAJBF16
- CAGE
- AH573
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Other
- SAM.gov registration date
- Physical address
- Via Mario Negri, 2, 20156 Milano MI, Italy
- Website
- marionegri.it
- Founded
- 1961
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Life Sciences Tools & Services
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Trustees Of Columbia University In The City Of New York | HT94252310384 | $23,348 | |
| The Trustees Of Columbia University In The City Of New York | R01NS134902 | $146,319 | |
| The Trustees Of Columbia University In The City Of New York | R01NS110024 | $82,004 | |
| The Trustees Of Columbia University In The City Of New York | R01NS134902 | $149,040 | |
| The Trustees Of Columbia University In The City Of New York | HT94252310384 | $24,448 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Istituto DI Ricerche Farmacologiche Mario Negri, a non-profit biomedical research organization based in Milan, Italy, receives federal grants as a prime recipient and serves as a sub-recipient on federally funded neuroscience research programs, with all recent activity concentrated in the Defense Health Agency and the National Institute of Neurological Disorders and Stroke (NINDS).
The organization operates as a sub-recipient on 75% of its federal awards (six of eight), primarily under Columbia University's prime grant from NINDS to study SUMOylation effects on tau aggregation and toxicity in neurodegenerative disease. The institute's sub-grant portfolio spans multiple collaborations with Columbia University on projects covering tau protein characterization, SUMO2-mimetic peptide development (PLB002 and PLB007), structural analysis via circular dichroism and transmission electron microscopy, and iPSC-derived neuron production for imaging and pharmacological studies. Luana Fioriti, PhD, serves as co-investigator and second principal investigator for the IRFMN component across these awards, with work performed at the institute's Via Mario Negri headquarters in Milan. Sub-award dates range from March 2024 through January 2026.
As a prime recipient, Istituto DI Ricerche Farmacologiche Mario Negri holds a $3.499 million Defense Health Agency project grant (CFDA 12.420, Military Medical Research and Development program) awarded September 1, 2026, and running through August 31, 2030. The grant, titled "Advancing SUMO2 Therapy Toward Clinical Application in Frontotemporal Dementia," supports basic and applied research to develop SUMO2-based therapeutic approaches for neurodegenerative disease, with place of performance in Italy.
Customer concentration is narrow and stable. The Defense Health Agency and NINDS together account for 100% of recent federal funding across five and three awards respectively. Combined dollars obligated across all eight awards total $4.5 million. Activity shows recent acceleration — one award in 2019, four in 2024, one in 2025, and two in 2026 — though the award count remains small relative to the organization's research profile. The institute does not hold federal contracts or contract vehicles; all federal engagement flows through grant and sub-grant mechanisms aligned to neuroscience and neurological disorder research portfolios.
Quick answers
Is Istituto DI Ricerche Farmacologiche Mario Negri registered in SAM.gov?
Yes. Istituto DI Ricerche Farmacologiche Mario Negri's SAM.gov registration is active through July 23, 2027.
What is Istituto DI Ricerche Farmacologiche Mario Negri's CAGE code?
Istituto DI Ricerche Farmacologiche Mario Negri's CAGE code is AH573, and its Unique Entity ID (UEI) is TN35LLAJBF16.
What is Istituto DI Ricerche Farmacologiche Mario Negri's most recent federal award?
Istituto DI Ricerche Farmacologiche Mario Negri's most recent federal grant award is Advancing SUMO2 therapy toward clinical application in frontotemporal dementia (HT9425261E385), from Defense Health Agency, on September 1, 2026.
On GovTribe
See Istituto DI Ricerche Farmacologiche Mario Negri's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors